A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Collaborator: Shionogi

Criteria

Inclusion Criteria:

• No prior HIV medications.

• HIV infection with viral load >400-50,000 copies/mL.

• CD4 cell count >50 cells/mm.

Exclusion Criteria:

• Patients requiring medications that cannot be interrupted for the duration of the study.

• Abnormal ECG or other chronic health conditions as noted on screening physical exam.

• Previous participation in an experimental drug trial(s) within 30 days of the screening visit for this study.